Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Obes ; 2020: 8026016, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32318289

RESUMEN

Background: Commercial weight loss programs provide valuable consumer options for those desiring support. Several commercial programs are reported to produce ≥3-fold greater weight loss than self-directed dieting. The effectiveness of JumpstartMD, a commercial pay-as-you-go program that emphasizes a low-to-very-low-carbohydrate real-food diet and optional pharmacologic treatment without prepackaged meals or meal replacement, has not previously been described. Methods: Completer and last observation carried forward (LOCF) of clinic-measured weight loss (kg) in 18,769 female and 3638 male JumpstartMD participants. Results: Completers lost (mean ± SE) 8.7 ± 0.04 kg, 9.5 ± 0.04% with 44.5 ± 0.5% achieving ≥10% weight loss at 3 months (mo, N = 14,999 completers); 11.8 ± 0.1 kg, 12.6 ± 0.1% with 66.4 ± 0.6% achieving ≥10% weight loss at 6 mo (N = 11,805); and 11.5 ± 0.2 kg, 12.0 ± 0.2% with 57.6 ± 0.9% achieving ≥10% weight loss at 12 mo (N = 8514). LOCF estimates were -6.5 ± 0.03 kg, -7.2 ± 0.03% with 27.1 ± 0.3% achieving ≥10% weight loss at 3 mo; -7.7 ± 0.04 kg, -8.5 ± 0.04% with 36.3 ± 0.3% achieving ≥10% weight loss at 6 mo; and -7.7 ± 0.1 kg, -8.4 ± 0.1% with 34.6 ± 0.3% achieving ≥10% weight loss after 12 mo. Frequent health coach meetings was a major determinant of weight loss, with women and men attending ≥75% of their weekly appointments losing 8.8 ± 0.04 and 11.9 ± 0.1 kg, respectively, after 3 mo, 13.1 ± 0.1 and 16.5 ± 0.3 kg after 6 mo, and 16.5 ± 0.3 and 19.4 ± 0.8 kg after 12 mo. Phentermine and phendimetrazine had a minor effect in women only at 1 (6.1% greater weight loss than untreated), 2 (4.1%), and 3 mo (1.2%), but treated patients showed longer enrollment than nontreated during the first 3 (females: +0.4 ± 0.01; males: +0.3 ± 0.04 mo), 6 (females: +1.1 ± 0.04; males: +1.0 ± 0.1 mo), and 12 mo (females: +2.7 ± 0.1; males: +2.4 ± 0.2 mo). JumpstartMD produced generally greater weight loss than published reports for other real-food and prepackaged-meal commercial programs and somewhat greater or comparable losses to meal replacement diets. Conclusion: A one-on-one medically supervised program that emphasized real low-carbohydrate foods produced effective weight loss, particularly in those attending ≥75% of their weekly appointments.


Asunto(s)
Obesidad/prevención & control , Adulto , Anciano , Dieta Reductora , Carbohidratos de la Dieta , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fentermina/administración & dosificación , Resultado del Tratamiento , Pérdida de Peso , Programas de Reducción de Peso
2.
J Occup Environ Med ; 60(1): 97-107, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-29303847

RESUMEN

OBJECTIVE: To conduct a comprehensive literature review to develop recommendations for managing obesity among workers to improve health outcomes and to explore the impact of obesity on health costs to determine whether a case can be made for surgical interventions and insurance coverage. METHODS: We searched PubMed from 2011 to 2016, and CINAHL, Scopus, and Cochrane Registry of Clinical Trials for interventions addressing obesity in the workplace. RESULTS: A total of 1419 articles were screened, resulting in 275 articles being included. Several areas were identified that require more research and investigation. CONCLUSIONS: Our findings support the use of both lifestyle modification and bariatric surgery to assist appropriate patients in losing weight.


Asunto(s)
Cobertura del Seguro , Seguro de Salud , Obesidad/terapia , Exposición Profesional/efectos adversos , Salud Laboral/normas , Seguridad , Cirugía Bariátrica/economía , Costos de la Atención en Salud , Humanos , Estilo de Vida , Obesidad/economía , Obesidad/etiología , Lugar de Trabajo
3.
Obesity (Silver Spring) ; 25 Suppl 2: S34-S39, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-29086516

RESUMEN

OBJECTIVE: Given the increasing evidence that obesity increases the risk of developing and dying from malignancy, the American Society of Clinical Oncology (ASCO) launched an Obesity Initiative in 2013 that was designed to increase awareness among oncology providers and the general public of the relationship between obesity and cancer and to promote research in this area. Recognizing that the type of societal change required to impact the obesity epidemic will require a broad-based effort, ASCO hosted the "Summit on Addressing Obesity through Multidisciplinary Collaboration" in 2016. METHODS: This meeting was held to review current challenges in addressing obesity within the respective health care provider communities and to identify priorities that would most benefit from a collective and cross-disciplinary approach. RESULTS: Efforts focused on four key areas: provider education and training; public education and activation; research; and policy and advocacy. Summit attendees discussed current challenges in addressing obesity within their provider communities and identified priorities that would most benefit from multidisciplinary collaboration. CONCLUSIONS: A synopsis of recommendations to facilitate future collaboration, as well as examples of ongoing cooperative efforts, provides a blueprint for multidisciplinary provider collaboration focused on obesity prevention and treatment.


Asunto(s)
Neoplasias/complicaciones , Obesidad/prevención & control , Grupo de Atención al Paciente , Guías como Asunto , Humanos , Oncología Médica , Obesidad/complicaciones , Sociedades Médicas , Estados Unidos
4.
Endocrinol Metab Clin North Am ; 45(3): 647-56, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27519136

RESUMEN

Bariatric surgery is the most efficient and long-lasting weight loss therapy available. Its safety has improved over tenfold over the last decade. With the advent of laparoscopy, mortality rates of are now under 1 per 1400 cases in accredited centers. Gastric bypass reduces diabetes-related mortality by 92% over 7 years and long lasting remission has been demonstrated in observational studies covering >10,000 patients and multiple randomized control trials. The benefit of bariatric surgery on diabetes is so substantial that these procedures should be considered in all type 2 diabetic patients with a BMI > 35 kg/m(2).


Asunto(s)
Cirugía Bariátrica , Obesidad Mórbida/cirugía , Pérdida de Peso , Diabetes Mellitus Tipo 2/cirugía , Derivación Gástrica , Humanos , Laparoscopía , Estudios Observacionales como Asunto , Ensayos Clínicos Controlados Aleatorios como Asunto
5.
Surg Clin North Am ; 96(4): 733-42, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27473798

RESUMEN

Patient safety and quality improvement have been part of bariatric surgery since its inception, and there have been significant improvements in outcomes of bariatric surgery over the past 2 decades. A strong accreditation program exists. This program defines 2 tiers of accredited centers: low-acuity and comprehensive centers similar to the trauma systems. Accreditation has been shown to have a favorable impact on outcomes of bariatric surgery. Bariatric surgery lends itself well to improvements in processes and use of perioperative protocols, such as ulcer and thromboembolic prophylaxis prevention or gallstone prevention and management.


Asunto(s)
Cirugía Bariátrica/normas , Seguridad del Paciente , Mejoramiento de la Calidad , Acreditación , Cirugía Bariátrica/métodos , Humanos , Evaluación de Procesos y Resultados en Atención de Salud , Readmisión del Paciente , Complicaciones Posoperatorias/prevención & control , Estados Unidos
6.
Diabetes Care ; 39(6): 949-53, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-27222553

RESUMEN

Obesity and diabetes represent twin health concerns in the developed world. Metabolic surgery has emerged as an established and enduring treatment for both obesity and diabetes. As the burden of obesity and diabetes varies upon the basis of ethnicity, it is also apparent that there may be differences for indications and outcomes for different ethnic groups after metabolic surgery. Whereas there appears to be evidence for variation in weight loss and complications for different ethnic groups, comorbidity remission particularly for diabetes appears to be free of ethnic disparity after metabolic surgery. The impacts of access, biology, culture, genetics, procedure, and socioeconomic status upon metabolic surgery outcomes are examined. Further refinement of the influence of ethnicity upon metabolic surgery outcomes is likely imminent.


Asunto(s)
Cirugía Bariátrica , Etnicidad , Cirugía Bariátrica/estadística & datos numéricos , Comorbilidad , Complicaciones de la Diabetes/etnología , Complicaciones de la Diabetes/cirugía , Diabetes Mellitus/etnología , Diabetes Mellitus/cirugía , Etnicidad/estadística & datos numéricos , Humanos , Obesidad/complicaciones , Obesidad/etnología , Obesidad/cirugía , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...